vs

Side-by-side financial comparison of Cellebrite DI Ltd. (CLBT) and Guardian Pharmacy Services, Inc. (GRDN). Click either name above to swap in a different company.

Guardian Pharmacy Services, Inc. is the larger business by last-quarter revenue ($336.6M vs $292.2M, roughly 1.2× Cellebrite DI Ltd.). Guardian Pharmacy Services, Inc. runs the higher net margin — 4.0% vs -103.5%, a 107.5% gap on every dollar of revenue.

Cellebrite DI Ltd. is a digital forensics company headquartered in Petah Tikva, Israel that provides tools for law enforcement agencies as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Their flagship product series is the Cellebrite UFED.

CVS Pharmacy Inc. is an American retail corporation. A subsidiary of CVS Health, it is headquartered in Woonsocket, Rhode Island. Originally named the Consumer Value Stores, it was founded in Lowell, Massachusetts, in 1963.

CLBT vs GRDN — Head-to-Head

Bigger by revenue
GRDN
GRDN
1.2× larger
GRDN
$336.6M
$292.2M
CLBT
Higher net margin
GRDN
GRDN
107.5% more per $
GRDN
4.0%
-103.5%
CLBT

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
CLBT
CLBT
GRDN
GRDN
Revenue
$292.2M
$336.6M
Net Profit
$-302.3M
$13.5M
Gross Margin
84.6%
22.7%
Operating Margin
14.1%
5.3%
Net Margin
-103.5%
4.0%
Revenue YoY
2.2%
Net Profit YoY
46.1%
EPS (diluted)
$-1.50
$0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLBT
CLBT
GRDN
GRDN
Q1 26
$336.6M
Q4 25
$397.6M
Q3 25
$292.2M
$377.4M
Q2 25
$220.8M
$344.3M
Q1 25
$89.6M
$329.3M
Q3 24
$232.1M
$314.4M
Q2 24
$185.3M
Q1 24
$71.2M
Net Profit
CLBT
CLBT
GRDN
GRDN
Q1 26
$13.5M
Q4 25
$20.9M
Q3 25
$-302.3M
$9.8M
Q2 25
$36.9M
$9.0M
Q1 25
$-71.4M
$9.4M
Q3 24
$-122.0M
Q2 24
$-95.2M
Q1 24
$-40.6M
Gross Margin
CLBT
CLBT
GRDN
GRDN
Q1 26
22.7%
Q4 25
21.5%
Q3 25
84.6%
19.8%
Q2 25
84.1%
19.8%
Q1 25
85.2%
19.5%
Q3 24
83.5%
19.4%
Q2 24
84.1%
Q1 24
82.6%
Operating Margin
CLBT
CLBT
GRDN
GRDN
Q1 26
5.3%
Q4 25
7.7%
Q3 25
14.1%
4.3%
Q2 25
12.1%
3.7%
Q1 25
10.3%
3.9%
Q3 24
7.9%
-33.3%
Q2 24
11.7%
Q1 24
0.2%
Net Margin
CLBT
CLBT
GRDN
GRDN
Q1 26
4.0%
Q4 25
5.3%
Q3 25
-103.5%
2.6%
Q2 25
16.7%
2.6%
Q1 25
-79.7%
2.9%
Q3 24
-38.8%
Q2 24
-51.4%
Q1 24
-57.0%
EPS (diluted)
CLBT
CLBT
GRDN
GRDN
Q1 26
$0.21
Q4 25
Q3 25
$-1.50
Q2 25
$0.15
Q1 25
$-0.36
Q3 24
$-0.35
Q2 24
$-0.48
Q1 24
$-0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLBT
CLBT
GRDN
GRDN
Cash + ST InvestmentsLiquidity on hand
$191.7M
$64.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$336.0M
$232.4M
Total Assets
$690.6M
$426.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLBT
CLBT
GRDN
GRDN
Q1 26
$64.9M
Q4 25
$65.6M
Q3 25
$191.7M
$36.5M
Q2 25
$326.1M
$18.8M
Q1 25
$191.7M
$14.0M
Q3 24
$189.5M
$37.2M
Q2 24
$178.6M
Q1 24
$189.5M
Total Debt
CLBT
CLBT
GRDN
GRDN
Q1 26
Q4 25
$0
Q3 25
Q2 25
Q1 25
Q3 24
$34.3M
Q2 24
Q1 24
Stockholders' Equity
CLBT
CLBT
GRDN
GRDN
Q1 26
$232.4M
Q4 25
$217.9M
Q3 25
$336.0M
$195.5M
Q2 25
$408.4M
$179.7M
Q1 25
$336.0M
$163.2M
Q3 24
$34.2M
$133.9M
Q2 24
$-40.2M
Q1 24
$34.2M
Total Assets
CLBT
CLBT
GRDN
GRDN
Q1 26
$426.9M
Q4 25
$412.7M
Q3 25
$690.6M
$390.0M
Q2 25
$787.4M
$356.3M
Q1 25
$690.6M
$334.0M
Q3 24
$532.9M
$348.0M
Q2 24
$556.6M
Q1 24
$532.9M
Debt / Equity
CLBT
CLBT
GRDN
GRDN
Q1 26
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
Q3 24
0.26×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLBT
CLBT
GRDN
GRDN
Operating Cash FlowLast quarter
$66.2M
$6.1M
Free Cash FlowOCF − Capex
$60.8M
FCF MarginFCF / Revenue
20.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
0.45×
TTM Free Cash FlowTrailing 4 quarters
$172.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLBT
CLBT
GRDN
GRDN
Q1 26
$6.1M
Q4 25
$34.6M
Q3 25
$66.2M
$28.2M
Q2 25
$53.5M
$19.9M
Q1 25
$10.0M
$17.6M
Q3 24
$58.2M
Q2 24
$24.6M
Q1 24
$12.5M
Free Cash Flow
CLBT
CLBT
GRDN
GRDN
Q1 26
Q4 25
Q3 25
$60.8M
$24.2M
Q2 25
$47.5M
Q1 25
$8.5M
Q3 24
$55.3M
Q2 24
$21.0M
Q1 24
$11.4M
FCF Margin
CLBT
CLBT
GRDN
GRDN
Q1 26
Q4 25
Q3 25
20.8%
6.4%
Q2 25
21.5%
Q1 25
9.5%
Q3 24
23.8%
Q2 24
11.3%
Q1 24
16.0%
Capex Intensity
CLBT
CLBT
GRDN
GRDN
Q1 26
Q4 25
Q3 25
1.8%
1.1%
Q2 25
2.7%
Q1 25
1.7%
Q3 24
1.3%
Q2 24
1.9%
Q1 24
1.5%
Cash Conversion
CLBT
CLBT
GRDN
GRDN
Q1 26
0.45×
Q4 25
1.65×
Q3 25
2.87×
Q2 25
1.45×
2.21×
Q1 25
1.86×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLBT
CLBT

Subscription services$197.2M67%
Term-license$60.8M21%
Professional services$23.2M8%
Other non-recurring$11.0M4%

GRDN
GRDN

Segment breakdown not available.

Related Comparisons